10x Genomics (TXG) Competitors $11.92 -1.09 (-8.38%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$12.02 +0.10 (+0.80%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TXG vs. ADPT, PACB, TWST, VCYT, VNT, MIR, ST, CAMT, TRNS, and EYPTShould you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Adaptive Biotechnologies (ADPT), Pacific Biosciences of California (PACB), Twist Bioscience (TWST), Veracyte (VCYT), Vontier (VNT), Mirion Technologies (MIR), Sensata Technologies (ST), Camtek (CAMT), Transcat (TRNS), and Eyepoint Pharmaceuticals (EYPT). 10x Genomics vs. Its Competitors Adaptive Biotechnologies Pacific Biosciences of California Twist Bioscience Veracyte Vontier Mirion Technologies Sensata Technologies Camtek Transcat Eyepoint Pharmaceuticals 10x Genomics (NASDAQ:TXG) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Which has more risk and volatility, TXG or ADPT? 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Do insiders and institutionals have more ownership in TXG or ADPT? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 10.0% of 10x Genomics shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, TXG or ADPT? Adaptive Biotechnologies has lower revenue, but higher earnings than 10x Genomics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.40-$182.63M-$1.30-9.17Adaptive Biotechnologies$178.96M9.97-$159.49M-$0.96-12.23 Does the media refer more to TXG or ADPT? In the previous week, Adaptive Biotechnologies had 4 more articles in the media than 10x Genomics. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 3 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 1.57 beat Adaptive Biotechnologies' score of 0.50 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer TXG or ADPT? 10x Genomics presently has a consensus price target of $14.96, indicating a potential upside of 25.52%. Adaptive Biotechnologies has a consensus price target of $10.57, indicating a potential downside of 9.95%. Given 10x Genomics' higher probable upside, analysts clearly believe 10x Genomics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.43Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Is TXG or ADPT more profitable? 10x Genomics has a net margin of -25.14% compared to Adaptive Biotechnologies' net margin of -74.84%. 10x Genomics' return on equity of -23.22% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Adaptive Biotechnologies -74.84%-62.79%-24.55% Summary10x Genomics beats Adaptive Biotechnologies on 10 of the 16 factors compared between the two stocks. Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXG vs. The Competition Export to ExcelMetric10x GenomicsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.60B$2.00B$5.52B$9.02BDividend YieldN/AN/A5.24%4.08%P/E Ratio-9.1735.1027.2620.04Price / Sales2.4011.78381.2593.27Price / CashN/A55.8726.2128.59Price / Book2.058.497.945.55Net Income-$182.63M-$62.39M$3.17B$248.49M7 Day Performance-1.16%1.37%1.80%4.87%1 Month Performance26.54%1.65%1.28%6.63%1 Year Performance-35.39%5.22%33.57%20.38% 10x Genomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXG10x Genomics4.9101 of 5 stars$11.92-8.4%$14.96+25.5%-36.3%$1.60B$610.78M-9.171,240Positive NewsADPTAdaptive Biotechnologies3.4201 of 5 stars$11.65-1.2%$10.57-9.3%+231.6%$1.77B$189.53M-12.14790PACBPacific Biosciences of California2.4777 of 5 stars$1.24-3.9%$2.06+66.2%+12.2%$372.10M$154.01M-0.44730Gap DownTWSTTwist Bioscience4.5231 of 5 stars$36.79+2.4%$50.40+37.0%-26.6%$2.20B$312.97M-11.32990News CoveragePositive NewsVCYTVeracyte3.7565 of 5 stars$27.03-1.3%$40.90+51.3%+22.3%$2.12B$445.76M65.93790Positive NewsVNTVontier3.4985 of 5 stars$36.94-0.2%$44.83+21.4%-0.6%$5.46B$2.98B15.028,000MIRMirion Technologies0.8994 of 5 stars$21.59-0.6%$18.75-13.2%+92.8%$5.01B$860.80M-359.832,860Positive NewsSTSensata Technologies4.2833 of 5 stars$30.13+0.6%$34.08+13.1%-16.7%$4.41B$3.93B37.2019,000CAMTCamtek2.6476 of 5 stars$84.56+0.1%$88.56+4.7%-32.7%$3.86B$450.86M32.40400Analyst ForecastTRNSTranscat2.3788 of 5 stars$85.96+1.3%$114.00+32.6%-29.4%$801.15M$278.42M55.101,245EYPTEyepoint Pharmaceuticals2.6954 of 5 stars$9.41-2.4%$25.67+172.8%+11.8%$647.50M$43.27M-3.90120 Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Pacific Biosciences of California Alternatives Twist Bioscience Alternatives Veracyte Alternatives Vontier Alternatives Mirion Technologies Alternatives Sensata Technologies Alternatives Camtek Alternatives Transcat Alternatives Eyepoint Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TXG) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
